Nanoliposomal irinotecan for patients with metastatic pancreatic cancer

Abstract

Some anticancer agents-incorporating liposomes have been developed and exhibited the clinical benefits. Recently, a novel nanoliposomal formulation of irinotecan (Onyvide®) has been approved in combination with 5―FU and leucovorin for the treatment of patients with metastatic pancreatic cancer. In this review, we introduce the characteristics and clinical trials of the nanoliposomal irinotecan.